| Original language | English (US) |
|---|---|
| Pages (from-to) | 615-617 |
| Number of pages | 3 |
| Journal | JAMA Oncology |
| Volume | 9 |
| Issue number | 5 |
| DOIs |
|
| State | Published - May 18 2023 |
Bibliographical note
Funding Information:Additional Contributions: I thank the investigators of this trial and all researchers in the field advancing knowledge of colorectal cancers for the benefit of patients. I thank Mr and Mrs Dick and Lynnae Koats; Mr and Mrs Leo and Madeleine Luskey; Mrs Patricia Johnson; the Mu Sigma Chapter of the Phi Gamma Delta Fraternity, University of Minnesota (FIJI); the Litman Family Fund for Cancer Research; Friends and Family of Gayle Huntington; and Love Like Laurie Legacy for financial support of cancer research in the Lou Lab at the University of Minnesota.
Funding Information:
Conflict of Interest Disclosures: Dr Lou reported receiving research grants from the American Cancer Society (RSG-22-022-01-CDP) and the Minnesota Ovarian Cancer Alliance; receiving honoraria and travel expenses from GlaxoSmithKline and Novocure; receiving equipment for laboratory-based research from Novocure; receiving an honorarium from Daiichi-Sankyo (donated to his laboratory); receiving fees from Elsevier Publishing and Johns Hopkins Press; consulting for Nomocan Pharmaceuticals; serving as a scientific advisory board member for Minnetronix, LLC; receiving consulting fees and a speaker honorarium from Boston Scientific; serving as institutional principal investigator for clinical trials sponsored by Celgene, Novocure, Intima Biosciences, and the National Cancer Institute; and having University of Minnesota membership in the Caris Life Sciences Precision Oncology Alliance.
PubMed: MeSH publication types
- Editorial
- Comment
